Mainz Biomed (NASDAQ:MYNZ – Free Report) – Research analysts at HC Wainwright boosted their Q3 2024 earnings estimates for shares of Mainz Biomed in a research report issued on Monday, November 25th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.11) per share for the quarter, up from their previous forecast of ($0.18). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Mainz Biomed’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2024 earnings at ($0.09) EPS and FY2024 earnings at ($0.59) EPS.
Mainz Biomed Stock Performance
MYNZ stock opened at $0.26 on Wednesday. Mainz Biomed has a 52 week low of $0.19 and a 52 week high of $1.79. The company’s 50-day simple moving average is $0.26 and its 200 day simple moving average is $0.39.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Featured Stories
- Five stocks we like better than Mainz Biomed
- What Are Dividend Challengers?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- What is a SEC Filing?
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Are Dividend Achievers? An Introduction
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
